PDS Biotechnology Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 31

Employees

  • Stock Symbol
  • PDSB

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.56
  • (As of Friday Closing)

PDS Biotechnology General Information

Description

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Contact Information

Formerly Known As
Edge Therapeutics, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 303A College Road East
  • Princeton, NJ 08540
  • United States
+1 (800)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 303A College Road East
  • Princeton, NJ 08540
  • United States
+1 (800)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PDS Biotechnology Stock Performance

As of 14-Feb-2025, PDS Biotechnology’s stock price is $1.56. Its current market cap is $58.4M with 37.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.56 $1.50 $1.25 - $6.68 $58.4M 37.4M 332K -$1.17

PDS Biotechnology Financials Summary

As of 30-Sep-2024, PDS Biotechnology has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 107,296 123,959 328,034 161,125
Revenue 0 0 0 0
EBITDA (39,347) (43,028) (41,672) (21,434)
Net Income (40,556) (42,942) (40,855) (16,918)
Total Assets 52,451 59,390 77,008 67,198
Total Debt 24,669 23,852 23,473 490
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PDS Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PDS Biotechnology‘s full profile, request access.

Request a free trial

PDS Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the
Biotechnology
Princeton, NJ
31 As of 2024

Hayward, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PDS Biotechnology Competitors (71)

One of PDS Biotechnology’s 71 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arcus Biosciences Formerly VC-backed Hayward, CA
Aura Biosciences Formerly VC-backed Cambridge, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
Rakuten Medical Venture Capital-Backed San Diego, CA
BriaCell Therapeutics Corporation West Vancouver, Canada
You’re viewing 5 of 71 competitors. Get the full list »

PDS Biotechnology Patents

PDS Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240316178-A1 Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof Pending 21-Oct-2022
US-20240317828-A1 T cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancers Pending 19-Oct-2022
US-20240317833-A1 Non-hla restricted t cell vaccine for tcr gamma alternate reading frame protein (tarp) protein expressing cancers Pending 17-Oct-2022
US-20220160867-A1 Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection Pending 20-Nov-2020
CA-3198708-A1 Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection Pending 20-Nov-2020 A61K39/39
To view PDS Biotechnology’s complete patent history, request access »

PDS Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PDS Biotechnology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PDS Biotechnology‘s full profile, request access.

Request a free trial

PDS Biotechnology Acquisitions (1)

PDS Biotechnology’s most recent deal was a Merger/Acquisition with Edge Therapeutics for . The deal was made on 15-Mar-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Edge Therapeutics 15-Mar-2019 Merger/Acquisition Other Healthcare Technology Systems
To view PDS Biotechnology’s complete acquisitions history, request access »

PDS Biotechnology ESG

Risk Overview

Risk Rating

Updated February, 15, 2024

35.44 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view PDS Biotechnology’s complete esg history, request access »

PDS Biotechnology FAQs

  • When was PDS Biotechnology founded?

    PDS Biotechnology was founded in 2005.

  • Where is PDS Biotechnology headquartered?

    PDS Biotechnology is headquartered in Princeton, NJ.

  • What is the size of PDS Biotechnology?

    PDS Biotechnology has 31 total employees.

  • What industry is PDS Biotechnology in?

    PDS Biotechnology’s primary industry is Biotechnology.

  • Is PDS Biotechnology a private or public company?

    PDS Biotechnology is a Public company.

  • What is PDS Biotechnology’s stock symbol?

    The ticker symbol for PDS Biotechnology is PDSB.

  • What is the current stock price of PDS Biotechnology?

    As of 14-Feb-2025 the stock price of PDS Biotechnology is $1.56.

  • What is the current market cap of PDS Biotechnology?

    The current market capitalization of PDS Biotechnology is $58.4M.

  • Who are PDS Biotechnology’s competitors?

    Arcus Biosciences, Aura Biosciences, Kite Pharma, Rakuten Medical, and BriaCell Therapeutics are some of the 71 competitors of PDS Biotechnology.

  • What is PDS Biotechnology’s annual earnings per share (EPS)?

    PDS Biotechnology’s EPS for 12 months was -$1.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »